Overview

Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
The desogestrel (150 mg) in combination with ethinyl estradiol (EE, 30 mg) is known as Marvelon in European countries. Previous studies revealed that the Marvelon is good and safe for women. As a study from Thailand showed that the Marvelon to be effective and acceptable in Thai women. Moreover compared to Caucasian women, the incidences of irregular bleeding and side effects were apparently lower in these Asian women . Although Marvelon was used in many countries but it's efficacy didn't reported among Iranian women.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Tehran University of Medical Sciences
Treatments:
Desogestrel
Criteria
Inclusion Criteria:

being on married, being within 18-40 years old, having normal Body mass index (ranged from
20 to 27 kg/m2), don't use any OCP during 3 months ago, having a normal menstruation cycle
for the last three cycles, having at least one of following mental and behavioural symptoms
( Fatigue, mood changes, lack of energy, irritability, aggression, depression, decreased
concentration, decreased social relationships, having a greed and increased appetite to
eating food), having at least one of following physical symptoms (Breast sensitivity,
swelling and flatulence) and women tend to use OCP for six consecutive months.

Exclusion Criteria:

pregnancy, having Anorexia or Bulimia, doing breastfeeding, smoke cigarette, Taking
sleeping pills more than 3 days per month, Injection estrogen, progesterone or androgen
during the past 3 months, Contraindications for OCP (including: thrombophlebitis - Severe
liver disease - cerebrovascular accident and heart disease - unexplained uterine bleeding -
lupus - breast cancer - migraines - sickle cell anemia - Epilepsy - gallbladder disease -
kidney problems - varicocele and family history thrombosis).